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INTRODUCTION
Amniocentesis is considered the first invasive diag-nostic technique ever performed during pregnan-
cy, initially as a method to detect severe fetal anemia.
Only in the late 1960’s and early 1970’s it was used pri-
marily for genetic diagnosis in high-risk patients1. 
Since then and for more than 40 years, amniocente-
sis has played a leading role as an invasive diagnostic
procedure for the detection of chromosomally abnor-
mal fetuses. 
For a long time, prenatal aneuploidy screening was
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based solely on maternal age and, therefore, that was
the main indication for amniocentesis. The intro -
duction of combined biochemical and ultrasound
markers changed the paradigm of prenatal diagnosis:
no longer should maternal age per se be considered the
sole marker 2. Combined screening improved the sen-
sitivity of screening and diminished false positive re-
sults, reducing the number of cases with indication for
invasive procedures. 
However, the definite diagnosis of chromosomal
abnormalities in the antenatal period is still only pos-
sible through invasive techniques and, despite the shift
towards earlier testing namely with chorionic villus
sampling, amniocentesis is still a highly valued tech-
nique. 
The main objective of this study was to characteri -
ze a population of pregnant women submitted to am-
niocentesis in a tertiary hospital, and to assess the
diagnos tic yield regarding fetal karyotype as well as
pregnancy outcomes. This information is useful to
counsel future pregnant women, as this represents a
reference unit in Portugal and national data are scarce.
METHODS
An observational retrospective study was performed
in the Prenatal Diagnosis Unit of São João Hospital
Center, with the approval of the Ethics Committee of
the institution. The Prenatal Diagnosis Unit in São
João Hospital Center, a tertiary and university hospi-
tal with differentiated perinatal care, performs inva-
sive procedures for fetal karyotype studies not only in
those cases screened in the Hospital, but also in cases
referred from other hospitals, essentially from the
North of Portugal, for diagnosis and counselling. 
We searched the database of the Genetics Depart-
ment for all products obtained by invasive procedures
performed during pregnancy between June 2003 and
June 2011, in order to identify the amniocenteses per-
formed during that period. In this analysis only sin-
gleton gestations were included. From June 2003 to
June 2011, a total of 1551 amniocentesis were per-
formed, of which 1444 in singleton pregnancies.
Maternal demographics, indication for amniocen-
tesis, gestational age at the time of amniocentesis, cy-
togenetic results, procedure-related complications du -
ring pregnancy and pregnancy outcome data were ex-
tracted from patient’s physical and electronic medical
records. For patients delivering outside our hospital or
whenever the information needed was not available, a
questionnaire was sent by mail to be retrieved by one
of the investigators (via regular post or email). Of the
1444 singleton pregnancies punctured, 86 (6%) were
ex cluded due to missing information regarding opera-
tor, gestational age at procedure or outcome of
pregnan cy. Complete data were thus obtained for 1358
cases.
All procedures were performed under ultrasound
guidance by senior staff obstetricians with special train-
ing in invasive procedures or supervised by them and
performed by junior obstetricians. No procedures were
performed by residents. Amniocentesis was performed
with a 21-Gauge needle and, in the majority of cases,
15 mL of amniotic fluid was collected. From all amnio -
tic fluid samples received in the laboratory, culture
failed in 2 cases (0.14%).
The outcome was classified as termination of pre -
gnancy (TOP), miscarriage if it concerned a sponta-
neous abortion before 24 weeks of gestation, in-
trauterine death or stillbirth after 24 weeks and delive -
ry of a liveborn child. Postprocedural miscarriage rate
was defined as spontaneous abortion or fetal demise
(before 24 weeks gestation) after amniocentesis. Total
pregnancy loss comprised all miscarriages, intrauterine
deaths or stillbirths. Fetal loss and premature rupture
of membranes within 2-weeks of procedure were also
evaluated.
Statistical analysis was performed in Stata® version
11.1 for Windows (StataCorp LP, College Station,
TX).      
RESULTS
The distribution of maternal age at the time of the pro-
cedure is shown in Table I. Overall, 56.5% of the pro-
cedures were performed in women aged 35 years or
more and the proportion of invasive tests performed in
this age group remained the same during the study pe-
riod (p=0.409).
Regarding the clinical indications for amniocente-
sis, the most frequent was maternal age ≥ 35 years
(32.2%), followed by positive prenatal screening
(30.9%), either first trimester combined screening or
second trimester triple screening  or integrated screen-
ing ; ultrasound markers of aneuploidy (13.4%); ultra-
sonographically detected malformations (12.9%); se-
roconversion (maternal infections) (3.5%); previous
child with chromosomal abnormality (3.3%); parent
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carrier of chromosome abnormality (1.9%); maternal
anxiety (1.6%) and miscellaneous (0.4%). The propor-
tion of amniocenteses performed due to maternal age
decreased significantly along the study period, from
over 50% to less than 10% (p<0.001). In contrast, the
proportion of invasive procedures performed for posi -
tive prenatal screening increased significantly over time
up to more than 40% (p<0.001) (Figure 1).The pro-
portion of amniocentesis performed for the remaining
indications did not have a meaningful variation along
the 8-year period. 
Out of the 1356 karyotypes obtained, 86 presented
chromosomal abnormalities (6,3%). Of those, 38
(44%) had trisomy 21, 12 presented trisomy 18 (14%)
and 9 had monosomy X (10%) The clinical indications
with highest positive predictive values were parent car-
rier of chromosome abnormality (46.2%), ultrasono-
graphically detected malformations (16.7%) and ul-
trasound markers of aneuploidy (14.3%) (Table II).
The amniocenteses were done between 12 and 39
weeks. The proportion of procedures performed be-
fore 16 weeks was 2.8% and it remained similar
throughout the study period (p=0.16).  Ninety-nine
amniocenteses were performed at 24 weeks or more,
representing 7.2% of the total of cases analysed.
Regarding the outcome of pregnancy after amnio-
centesis, ten pregnancies ended in a miscarriage (< 24-
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FIGURE 1. Proportion of procedures performed for maternal age and positive prenatal screening (PPS)
TABLE I. DISTRIBUTION OF MATERNAL AGE AT THE TIME OF THE PROCEDURE, ACCORDING TO CALENDAR YEAR
(P=0.409) 
Maternal age
Year < 30 years 30-34 years 35-39 years ≥ 40 years Total
2003 9 (17.3) 13 (25.0) 19 (36.5) 11 (21.2) 52
2004 25 (19.8) 24 (19.1) 54 (42.9) 23 (18.3) 126
2005 30 (19.0) 28 (17.7) 77 (48.7) 23 (14.6) 158
2006 35 (21.3) 40 (24.4) 64 (39.0) 25 (15.2) 164
2007 30 (16.6) 47 (26.0) 75 (41.4) 29 (16.0) 181
2008 46 (21.2) 60 (27.7) 76 (35.0) 35 (16.1) 217
2009 36 (19.5) 49 (26.5) 81 (43.8) 19 (10.3) 185
2010 40 (18.1) 50 (22.6) 86 (38.9) 45 (20.4) 221
2011 10 (18.5) 19 (35.2) 17 (31.5) 8 (14.8) 54
Overall 261 (19.2) 330 (24.3) 549 (40.4) 218 (16.1) 1,358
Data are count (%) of cases
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carriage rate of 0.7%. Twenty-two pregnancies ended
in a fetal death (ten before and twelve after 24 weeks’
gestation), representing a total pregnancy loss rate of
1.6%. There were 116 cases of TOP (8.5%) and the
proportion did not change throughout the study, as
none of the other outcomes (p=0.164) (Table III).  Fo-
cusing on pregnancies presenting with a normal karyo -
type and that were not terminated, fetal loss was
1.56%, which is significantly different from fetal loss
among those with abnormal karyotype (11%, p<0.001)
but similar to total pregnancy loss rate.
Among pregnancies that were not interrupted, fe-
tal loss risk within 2 weeks of the procedure was 0.4%
(95%CI 0.1-0.9) and the incidence of premature ru -
pture of membranes within 2 weeks was 0.37%. There
was no association between the operator and fetal loss
within 2 weeks of procedure (ranging from 0 to 2%,
p=0.89). The proportion of amniocenteses with  more
than one needle insertion was 3%, brownish/hematic
fluid occurred in 2.7% and transplacental puncture in
15%, with no association with fetal loss within 2 weeks
of procedure (p= 0.12, p= 0.64 and p= 0.84, respecti -
vely).
DISCUSSION
In this study, we present a review of our Prenatal Dia -
g nosis Centre experience across 8 years.  During the
study period, of the 1358 samples studied, cytogene -
tic results were obtained in 99.9% of the cases. In fact
our culture failure rate is very low probably because the
TABLE II. CLINICAL INDICATIONS FOR AMNIOCENTESIS AND THEIR POSITIVE PREDICTIVE VALUE (PPV) FOR 
ABNORMAL KARYOTYPE  
Number Number with 
Indications of cases chromosome abnormalities PPV (%)
Maternal age 437 5 1.14
Anxiety 21 0 0
Positive combined screening 419 14 3.34
Ultrasound markers 182 26 14.3
Ultrasound malformations 174 29 16.7
Seroconversion 47 0 0
Previous child with chromosomal abnormality 45 0 0
Parent carrier of chromosome abnormality 26 12 46.2
Miscellaneous 5 0 0
Total 1356 86
Data are count (%) of cases
TABLE III. OUTCOME OF PREGNANCY AFTER 
AMNIOCENTESIS
Outcome
Year Liveborn Miscarriage IUD TOP Total
2003 48 0 1 3 52
92.3 0.0 1.9 5.8
2004 112 1 2 11 126
88.9 0.8 1.6 8.7
2005 147 1 2 8 158
93.0 0.6 1.3 5.1
2006 145 1 3 15 164
88.4 0.6 1.8 9.2
2007 153 1 2 25 181
84.5 0.6 1.1 13.8
2008 198 0 0 19 217
91.2 0.0 0.0 8.8
2009 175 1 1 8 185
94.6 0.5 0.5 4.3
2010 193 5 1 22 221
87.3 2.3 0.5 10.0
2011 49 0 0 5 54
90.7 0.0 0.0 9.3
Total 1.220 10 12 116 1.358
89.84 0.74 0.88 8.54
IUD: intrauterine death; TOP: termination of pregnancy.
Data are count (top value, in bold font) and % (bottom value, normal
font) of cases.
(p=0.164 for the comparison of outcomes over the years)
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vast majority of the amniocenteses were performed
earlier in pregnancy when a greater concentration of
fetal cells is found. This is in good agreement with the
current literature and expectedly in our department
prenatal cytogenetic diagnosis in amniotic fluid sam-
ples is a highly reliable method to obtain fetal karyo -
type3.
Regarding clinical indications for invasive testing,
our results are similar to other published series 4, 5. Ma-
ternal age and positive combined prenatal screening
are the most frequent indications for cytogenetic study,
representing 63% of all clinical indications. However,
during the study period, a few changes occurred in the
prenatal diagnosis scenario. For many years, maternal
age was the only marker associated to Down syndrome
and represented the main clinical reason for referral
for invasive diagnostic procedures. However, maternal
age as selection criteria for invasive testing performed
poorly. Nowadays, a much more individualized risk as-
sessment is performed in most countries6. Biochemi-
cal markers, combined with nuchal translucency and
further ultrasound markers, such as nasal bone, ductus
venosus and tricuspid regurgitation, are progressively
replacing  maternal age as standard method for prena-
tal screening7.  In our study, that is clearly revealed by
the significant decrease of amniocentesis performed
for maternal age, opposed to the increase in invasive
testing performed because of positive prenatal scree -
ning. Nevertheless, the total number of amniocenteses
performed did not decline as would be expected as a
consequence of the more performant first trimester
screening, because the total number of referrals kept
steadily increasing. Only after 2011 there is an effec-
tive decline in the total number of amniocenteses be-
cause CVS was introduced routinely in the Depart-
ment.
It is known that karyotype abnormalities range be-
tween 1% and 6.7% in amniocenteses results5. In our
series, chromosome abnormalities were disclosed in
6.3% of the cases. Analyzing the frequency of chro-
mosome abnormalities for each clinical indication,
parental chromosomal rearrangements presented the
highest PPV (46.2%). This was an expected finding, as
progenitors with chromosomal rearrangements have a
high probability of transmitting it to descendants. Ex-
cluding this indication, clinical indications with high-
est VPP values are ultrasound malformations and ul-
trasound markers of aneuploidy, with 16.7% and
14.3%, respectively. This is also in agreement with lite -
rature data, confirming ultrasound examination im-
portant role in prenatal diagnosis screening for chro-
mosomal anomalies4,5. Low VPP value for positive pre-
natal screening , similarly to other studies5, might be
explained by the fact that not only positive combined
first-trimester screening were included, but also second
trimester positive screenings and positive integrated
screenings, which are less selective. 
Despite recent advances that promoted chorionic
villous sampling in invasive prenatal testing, amnio-
centesis still has a place in genetic diagnosis. Counse -
ling should include information regarding procedure-
associated complications. Fetal loss is considered the
major risk of second-trimester amniocentesis, as ma-
ternal risks are small and extremely rare.  In determi -
ning the total fetal loss rate, we have to acknowledge
the spontaneous background loss rates in the study
population and add it up to the procedure-related fe-
tal loss. Spontaneous background losses have been dif-
ficult to assess. The only randomized trial ever per-
formed, more than 25 years ago, reported a loss rate of
1.7% in the amniocentesis group and 0.7% in the con-
trol group8. However, in the present practice, per-
forming such a trial would be impractical, for ethical
concerns9. The traditional reported amniocentesis-re-
lated pregnancy loss, quoted by most of practitioners
when counseling women, has been stated as 1%. How-
ever, recent studies suggest lower procedure-related fe-
tal loss rates. 
A retrospective cohort study compared the fetal loss
rate in women who underwent a midtrimester amnio-
centesis with the fetal loss rate of those women that did
not have any invasive procedure and reported a fetal
loss rate attributable to the invasive procedure of only
0.13%10.  Also, the fetal loss rate presented in the First
and Second Trimester Evaluation of Risk (FASTER)
trial was 0.06 %8. It may be concluded that the present
numbers are consistent with a procedure-related mis-
carriage risk lower than 1%. 
In Portugal, national data are limited and the refer-
ral profile of our centre further supports the impor-
tance of reporting information regarding procedure-
associated fetal loss. 
Definitions concerning what should really be con-
sidered fetal losses attributable to invasive procedure
are far from being consensual. In fact, a systematic re-
view aiming to compile complications related to am-
niocentesis, used various definitions for “procedure-re-
lated pregnancy losses” 11. As such, we chose to evalua -
te not only total pregnancy loss rate (all fetal deaths
during pregnancy), but also post-procedural miscar-
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riage rate (fetal death before 24 weeks) and fetal loss
risk within 2-weeks of procedure.  In our study, post-
procedural miscarriage rate was of 0.74%, comparable
to available literature numbers10,12. Total pregnancy loss
rate was 1.62%, which is similar to others in litera-
ture11,13. When excluding those pregnancies electively
terminated, the risk of fetal loss within 2-weeks of pro-
cedure was of 0.4%, comparable to previously stated
procedure-related fetal loss rates14.
As effective screening methods are being imple-
mented, the number of invasive procedures is steadily
declining, raising concerns regarding operator skills.
As fetal loss after amniocentesis is fortunately low, 
other complications are studied in order to evaluate
ope rator’s performance. Some of those complications
were evaluated in previous studies as potential varia bles
associated with fetal loss, such as multiple needle in-
sertion and “bloody tap”. 
Regarding multiple needle insertions, the propor-
tion in previous studies is highly variable, ranging from
0.2% to 2.9 %11. In our study, the proportion of am-
niocentesis needing more than one needle insertion
was 3%. It is unlikely that needle size has a significant
importance in this matter, because series with similar
needle size have lower multiple insertion rates. Our
high rate might be due to the fact that, although the
majority of amniocentesis was performed by highly
skilled operators, 11.8% were performed by less expe-
rienced specialists, although supervised by senior ope -
rators.  However, previous published studies show that
there is no significant difference in fetal loss rate be-
tween only one needle insertion and multiple needle
insertion10. That is supported in our study that showed
no increase in fetal loss within 2-weeks of procedure in
the group with multiple needle insertions.
About transplacental puncture, although there is no
randomized approach to this question, a prospective
case-control study showed no significant difference in
fetal loss rate between non-transplacental and
transplacental amniocentesis6. Our results sustain tho -
se found previously, since fetal loss rate within 2-weeks
of procedure is similar with or without transplacental
puncture.
Bloody tap, potentially a surrogate measure of
opera tor performance, was found to be associated with
fetal loss15. However, in our study, there was no signifi -
cant difference in fetal loss rate within 2-weeks of pro-
cedure, regarding the presence of bloody tap.
Recent advances in prenatal diagnosis, such as the
possibility of fetal DNA analysis in maternal blood and
the increasing availability of CVS as a first trimester al-
ternative for diagnosis, might potentially decrease the
number of amniocentesis and, as such, evaluation of
centre and operator’s performance assumes further im-
portance. Recent studies in literature reinforce the
need to analyse institutional data in order to provide
benchmark data and quality control. 
The present study aimed to analyse the clinical in-
dications, outcomes and procedure related complica-
tions in our tertiary centre throughout an 8-year span.
Along these years, despite a meaningful shift in aneu-
ploidy screening, with advanced maternal age decli -
ning as referral for invasive procedures, amniocentesis
remained a valuable, reliable method for cytogenetic
analysis, with recognized clinical indications.
Although we collected a large quantity of data re-
garding amniocentesis, our study is limited by its retros -
pective design.  However, to our knowledge, it repre-
sents the first available and complete portuguese data
concerning this issue. Counselling is complex and im-
portant questions as procedure-related complications
and associated fetal loss have been inconsistently re-
ported, with significant variations from study to study.
As such, availability of institutional precise esti ma tes
regarding these important questions would be use ful
when advising women requesting amniocentesis.
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